Galapagos raising cash for new buyouts

Belgium's Galapagos is raising about $43 million in a new offering designed to help fund new acquisitions. Galapagos bought Argenta earlier this year for €16.5 million. "Management also remains ambitious to make Galapagos a European biotech leader, and acquisitions may help us to achieve that goal," said CEO Onno van de Stolpe. Story

Suggested Articles

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

Zydus Cadila has completed a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 .

OrbiMed, Novartis Venture Fund and RA Capital Management have joined forces to fund and help launch GentiBio.